Literature DB >> 10151048

Annual costs of benign prostatic hyperplasia in New Zealand.

W G Scott1, H M Scott.   

Abstract

Benign prostatic hyperplasia (BPH) has been regarded as part of the normal aging process in men and little attention has been focused on the cost of the disease in New Zealand. The purpose of this study was to estimate the direct and indirect costs of treating BPH in both the public and the private sectors in New Zealand. The costs of treatment were estimated from public and private hospital data on admissions for BPH, obtained from the New Zealand Department of Health, medical insurance reimbursement schedules, hospital ward costs at one centre, and urology and general practitioner consultation fees. The length of time spent off work, as a measure of indirect costs, during urological investigations or treatment was estimated from interviews with urologists. The annual 1991 total direct medical costs of treated BPH as primary diagnosis in New Zealand were estimated at $NZ16 million (the average of the end-month mid-point exchange rate for the first quarter of 1992 was $US0.5457 per $NZ1), and the costs of lost production plus loss of leisure time by patients was estimated at $NZ4 million (1992 dollars). Patients with a principal diagnosis of BPH stayed on average 8.9 days in a public hospital and 4.6 days in a private hospital. Based on the above costs, if the average length of stay of public hospital patients could be reduced to that of private hospital patients, then hospital ward costs for BPH could fall by 37% and the total direct medical costs by 21%. The most commonly performed surgical operation for BPH was transurethral prostatectomy (TURP). For operations performed in a public hospital, patients stayed on average 8.5 days, while patients whose operations were performed in private hospitals stayed 4.3 days. The mean age of these public hospital patients was 71 years compared with 67 years for those in private hospitals. A complication rate of 2.02% was recorded for TURP in public hospitals but audits (conducted by the researchers) in both public and private settings indicated that the complication rate was substantially under-recorded.

Entities:  

Mesh:

Year:  1993        PMID: 10151048     DOI: 10.2165/00019053-199304060-00007

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  5 in total

1.  Indirect costs in economic studies: confronting the confusion.

Authors:  M A Koopmanschap; F F Rutten
Journal:  Pharmacoeconomics       Date:  1993-12       Impact factor: 4.981

2.  Incontinence: the secret problem.

Authors:  H Crowder
Journal:  N Z Nurs J       Date:  1991-03

Review 3.  Epidemiology and natural history of benign prostatic hyperplasia.

Authors:  M J Barry
Journal:  Urol Clin North Am       Date:  1990-08       Impact factor: 2.241

Review 4.  Clinical manifestations of benign prostatic hyperplasia and indications for therapeutic intervention.

Authors:  M M Christensen; R C Bruskewitz
Journal:  Urol Clin North Am       Date:  1990-08       Impact factor: 2.241

5.  Factors associated with sexual dysfunction following transurethral resection of the prostate.

Authors:  P J Gilling; W L Wright; J M Gray
Journal:  N Z Med J       Date:  1988-07-27
  5 in total
  3 in total

1.  Critical leg ischaemia in New Zealand: economic cost of amputation versus intravenous iloprost.

Authors:  H M Scott; W G Scott
Journal:  Pharmacoeconomics       Date:  1994-08       Impact factor: 4.981

2.  A pharmacoeconomic analysis of patients with symptoms of benign prostatic hyperplasia.

Authors:  P C Cockrum; S F Finder; A J Ries; R P Potyk
Journal:  Pharmacoeconomics       Date:  1997-06       Impact factor: 4.981

3.  Healthcare utilization and costs in patients with benign prostatic hyperplasia: a population-based study.

Authors:  Shiu-Dong Chung; Ya-Mei Tzeng; Herng-Ching Lin; Chao-Yuan Huang
Journal:  Asian J Androl       Date:  2016 Nov-Dec       Impact factor: 3.285

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.